John Timberlake has served as our chief executive officer, president and chief commercial officer and a member of our board of directors since February 2016, prior to which he served as president and chief commercial officer since August 2008. Before becoming chief executive officer, president and chief commercial officer, Mr. Timberlake was a general manager with our company from September 2006 to August 2008. Prior to joining Valeritas, Mr. Timberlake held positions of increasing responsibility from 1991 to 2006 at Sanofi-Aventis (now Sanofi), with his last role as vice president of diabetes marketing, where he was responsible for the diabetes franchise, including the brands Lantus, Apidra and Amaryl. While at Sanofi, Mr. Timberlake had extensive experience and commercial responsibilities for new products in development across multiple therapeutic areas, including inhaled insulin and other metabolic products. Prior to working in the healthcare industry, Mr. Timberlake was a manager with Deloitte & Touche LLP from 1986 to 1991 and was both a certified management accountant and a certified public accountant. He earned a B.S. in Accounting at Northwest Missouri State University, an M.S. in management from Purdue University and an MBA from ESC Rouen in France (now NEOMA Business School).

Erick Lucera joined the company as Chief Financial Officer in August 2016. Prior to joining Valeritas, Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company’s product pipeline through a series of acquisitions and in licensing transactions financed through 5 public and private offerings of nearly $250 million. In 2012, he served as Vice President, Corporate Development at Sunshine Heart, a medical device manufacturer. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He holds a CPH from Harvard University, and MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.

Scott Huie joined Valeritas in 2002. He has over 30 years’ experience in medical device, pharmaceutical and combination products and has held roles in product/process development, operations, regulatory and quality. Scott was previously vice president, operations at Fusion Medical Technologies, which was acquired by Baxter Healthcare Corporation. He has also worked at Aradigm, Cygnus Therapeutic Systems, Ciba-Geigy and 3M Company. Scott received his Bachelor of Science in chemical engineering from Rensselaer Polytechnic Institute.

Mark Conley has served as vice president, corporate controller and treasurer since February 2016, prior to which he served as our director of financial planning & analysis since joining Valeritas in August 2012. Prior to joining Valeritas, Mark was global finance director of the radiation instrumentation business at Thermo Fisher Scientific from 2007 to 2012. In addition, he served at Iron Mountain, Inc. as vice president, financial planning & analysis from 2005 to 2007 and division controller from 1998 to 2004; as chief financial officer & controller at HoltraChem Group from 1996 to 1998; and in successive financial leadership roles, including operations controller at Haemonetics Corporation from 1991 to 1996. Mr. Conley earned a Bachelor of Science in accounting from Oklahoma State University and an MBA from Bryant College and is a certified public accountant.

David Lewis joined Valeritas in June 2016. Mr. Lewis brings with him more than 20 years of healthcare industry marketing experience having led product launch teams for both Merck and Bristol-Myers Squibb/AstraZeneca. Mr. Lewis has extensive experience in the diabetes market having served as Senior Director and Team Lead for Merck’s launch of Januvia® followed by his leadership over the global launch of Forxiga® during his tenure with AstraZeneca and Bristol-Myers Squibb as Executive Director of Marketing. Mr. Lewis has also led the development and execution of commercial strategies and plans for several smaller startup bio-pharma companies. Mr. Lewis holds a bachelor of science degree in engineering from Michigan State University and earned his MBA from Purdue University’s Krannert School of Management.